U.S. Rivaroxaban Market Set to Boom Rapidly by 2033 | Pfizer Inc. • Merck & Co. • Amgen Inc
Coherent Market Insights has published a new report detailing the "U.S. Rivaroxaban Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033." The report provides a comprehensive analysis of market percentage records, enterprise analysis, competition, geographic distribution, and growth potential, along with economic analysis and anticipated ROI. Major players like Bayer AG, Johnson & Johnson, Pfizer Inc., and Merck & Co. are included, and the report segments the market by cardiovascular disease, atrial fibrillation, venous thromboembolism, and other applications.
The Zacks Analyst Blog Duke Energy, Entergy, Constellation Brands, Coca-Cola and Johnson & Johnson
The Zacks Analyst Blog highlights five defensive stocks—Duke Energy, Entergy, Constellation Brands, Coca-Cola, and Johnson & Johnson—as prudent investments amidst recent market volatility caused by AI concerns, geopolitical tensions, and inflation. These companies, chosen for their stability in utility, consumer staples, and healthcare sectors, exhibit strong financials, dividend yields, and positive Zacks Ranks. The blog provides detailed insights into each company's strategic initiatives, growth projections, and market performance.
Is It Time To Reconsider Pfizer (PFE) After Diverging Valuation Narratives?
This article examines Pfizer's (PFE) valuation through two approaches: Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio, both indicating Pfizer is currently undervalued. It then introduces "Narratives"—bullish and bearish case scenarios with differing fair values and assumptions for revenue, margins, and pipeline success—to help investors frame their own valuation perspective.
Boston Scientific Just Took A 9% Header. Why Analysts Are Still Bullish.
Boston Scientific's stock (BSX) plummeted 9% to a two-year low after mixed test results for its Watchman FLX device, which prevents strokes. Despite the significant drop, analysts remain bullish on the medical device company, indicating confidence in the product's long-term potential or other aspects of the business. The Watchman FLX is a minimally invasive device designed to seal off the heart's left atrial appendage, where most blood clots form.
Kenvue Inc (KVUE) Stock Price Quote Today & Current Price Chart
This article provides a stock price quote and current price chart for Kenvue Inc (KVUE), the consumer health spin-off of Johnson & Johnson, known for brands like Tylenol and Neutrogena. It details CFD trading conditions, including spreads, overnight funding adjustments, and margin requirements. The content also features recent articles related to other company stock forecasts, such as Amazon, Siemens, Microsoft, and HENSOLDT.
Kenvue Inc (KVUE) Stock Price Quote Today & Current Price Chart
This article provides current stock price information and trading conditions for Kenvue Inc. (KVUE), the consumer health spin-off of Johnson & Johnson. It outlines CFD trading details such as spread, overnight funding adjustments, and commission, alongside key financial stats like previous close and 1-year change. The company is highlighted for its iconic brands and stable cash flows.
Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances
Lexeo Therapeutics updated its Q4 and full-year 2025 results, detailing advancements in its cardiac gene therapy pipeline and a strengthened financial position. The company ended 2025 with $246.6 million in cash, expected to fund operations into 2028, and made significant progress with LX2006 for Friedreich ataxia and LX2020 for PKP2 arrhythmogenic cardiomyopathy, including positive interim data and regulatory interactions. Lexeo also enhanced its leadership and collaborated with Johnson & Johnson, solidifying its position in cardiovascular genetic medicine despite an AI analyst ranking it as "Neutral" due to financial performance.
Pfizer (NYSE:PFE) Shares Up 2.6% - Time to Buy?
Pfizer (NYSE:PFE) shares rose 2.6% on Monday, driven by renewed interest in its GLP-1 program and its appeal as a high-dividend large-cap stock. Despite beating Q4 earnings expectations, analyst sentiment remains mixed-to-cautious with a "Hold" consensus and an average target price of $28.19. The company faces competitive pressures, particularly from peers like Eli Lilly, despite positive retail interest and long-term bullish commentary.
[8-K] Immix Biopharma, Inc. Reports Material Event
Immix Biopharma has completed enrollment for its NEXICART-2 Phase 2 trial of CAR-T therapy NXC-201 for relapsed/refractory AL amyloidosis, a 40-patient U.S. study. Topline results are anticipated in Q3 2026, which will be followed by a planned biologics license application submission and potential commercial launch. The company has also brought on a new Chief Medical Officer with significant prior experience at Merck and Johnson & Johnson to aid in the regulatory filing process.
Lexeo says cash lasts into 2028 as pivotal gene therapy trial nears
Lexeo Therapeutics reported its Q4 and full-year 2025 financial results, alongside significant progress in its cardiac genetic-medicine pipeline. The company announced $246.6 million in cash and investments, which it expects to fund operations into 2028, and highlighted FDA approvals and positive interim clinical data for its LX2006 and LX2020 programs. Lexeo also detailed plans for its pivotal SUNRISE-FA 2 trial, research collaboration with Johnson & Johnson, and strategic leadership appointments.
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Lexeo Therapeutics announced its fourth quarter and full year 2025 financial results and provided operational highlights, emphasizing significant advancements in its cardiac pipeline, particularly for LX2006 and LX2020. The company reported positive clinical data presentations at the American College of Cardiology Annual Meeting, strengthened its leadership team, and established a research collaboration with Johnson & Johnson. Lexeo also confirmed a cash position of $246.6 million, projected to fund operations into 2028.
Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies
Two large randomized trials presented at the American College of Cardiology meeting failed to demonstrate the benefits of Johnson & Johnson's miniaturized Impella heart pumps for patients with coronary artery blockages. One study found no benefit and a potential long-term harm for patients receiving Impella during PCI, while another study showed that using the pump before reopening coronary arteries in STEMI patients did not reduce heart damage and led to more bleeding complications. These findings challenge the routine use of Impella in certain high-risk PCI and STEMI scenarios despite their growing usage and J&J's earlier acquisition of Abiomed for these devices.
Should Positive ELIOS Glaucoma Trial Results Require Action From Bausch + Lomb (BLCO) Investors?
Bausch + Lomb (BLCO) reported positive 24-month results from its ELIOS excimer laser system trial for glaucoma treatment, showing significant intraocular pressure reduction and a strong medication-free rate. While these results could enhance Bausch + Lomb's long-term surgical offerings, the company still faces near-term challenges related to improving margins, reducing net losses, and managing high leverage. Investors are advised to consider the broader financial picture and the company's execution on 2026 revenue guidance as more immediate catalysts.
5 Defensive Stocks to Buy Amid Market's Recent Bloodbath
Amid severe market volatility in March, characterized by concerns over AI, geopolitical tensions, inflation, and interest rate uncertainty, Zacks Investment Research recommends investing in defensive stocks. The article highlights five low-beta stocks from the utilities, consumer staples, and healthcare sectors with favorable Zacks Ranks: Duke Energy Corp., Entergy Corp., Constellation Brands Inc., The Coca-Cola Co., and Johnson & Johnson. These companies are expected to offer stability and growth potential to protect portfolios during market downturns.
US Urges Court to Toss AstraZeneca’s Drug Price Negotiation Suit
The US government, represented by the Department of Justice, has asked a federal court to dismiss AstraZeneca Plc's lawsuit challenging a drug price negotiation program. The Centers for Medicare & Medicaid Services argues that a Biden-era law prohibits judicial review of this issue. The motion, filed on March 27, 2026, asserts that the US District Court for the District of Maryland lacks statutory subject-matter jurisdiction over the case.
The Low-Volatility Promise of ACWV Costs Investors 118% Over a Decade Compared to SPY
The iShares MSCI Global Min Vol Factor ETF (ACWV) is designed for investors seeking lower volatility and capital preservation, especially those in or near retirement. While it delivers on its promise of stability, particularly in volatile markets, it has significantly underperformed the S&P 500 over longer periods, costing investors 118% in foregone returns over a decade. The article highlights tradeoffs such as trailing during bull markets, modest international diversification despite its "global" label, and reduced appeal due to rising interest rates competing with its 1.79% dividend yield.
Immix fills amyloidosis trial; Q3 results tee up planned FDA filing
Immix Biopharma has completed enrollment for its BLA-enabling NEXICART-2 trial for relapsed/refractory AL amyloidosis, with topline results expected in Q3 2026. This milestone positions the company for a Biologics License Application (BLA) submission and a subsequent commercial launch. Immix also announced the appointment of Dr. Richard Graydon as Chief Medical Officer, bringing extensive experience in leading drug and biologic applications.
MeiraGTx (NASDAQ: MGTX) expands gene therapy partnerships and manufacturing
MeiraGTx details a robust gene therapy pipeline and strategic partnerships in its annual report, highlighting advancements in xerostomia, Parkinson's disease, and inherited retinal disorders. The company's in-house manufacturing capabilities and transformative riboswitch gene regulation platform are central to its strategy and supported by significant collaborations with Johnson & Johnson, Hologen, and Eli Lilly, which provide substantial non-dilutive capital and milestone potential. MeiraGTx has received FDA Breakthrough Therapy and RMAT designations for its lead programs, indicating strong potential for accelerated development and approval.
MeiraGTx 2025 10-K: Revenue $81.4M, EPS (1.42)
MeiraGTx reported 2025 fiscal revenue of $81.4 million, a significant increase from $33.3 million in 2024, primarily due to a $75.0 million license payment from Lilly. The company's net loss improved to $(114.2) million from $(147.8) million, and diluted net loss per share narrowed to $(1.42) from $(2.12). Key business highlights include strategic partnerships, regulatory milestones for its AAV programs, expansion of manufacturing capabilities, and advancements in its riboswitch platform.
As J&J Brings Icotyde to Market, AbbVie Remains Confident in Skyrizi’s Efficacy Edge
AbbVie is confident that its immunology drug, Skyrizi, maintains an efficacy advantage over Johnson & Johnson and Protagonist Therapeutics' newly approved oral pill, Icotyde, despite the latter entering the market for plaque psoriasis. Analysts at BMO Capital Markets note that Skyrizi offers superior efficacy and a less frequent dosing schedule, which patients may prefer over Icotyde's daily oral regimen. While Icotyde is expected to achieve significant sales, AbbVie believes Skyrizi will remain a key growth driver, supported by its strong clinical data.
Study data linked EXPAREL to lower knee and spine surgery costs
Pacira BioSciences presented real-world study data at the Orthopaedic Research Society 2026 Annual Meeting, indicating that its pain therapy EXPAREL is associated with lower total costs of care for patients undergoing total knee arthroplasty (TKA) and spinal fusion. The studies showed reduced 30-day total costs, decreased resource utilization, and shorter hospital stays for EXPAREL recipients compared to those receiving ropivacaine or other non-liposomal bupivacaine analgesia. These findings reinforce EXPAREL's economic value within multimodal pain management strategies.
Intuitive Surgical, Inc. stock: Leader in robotic-assisted surgery with strong growth potential for long-term investors
Intuitive Surgical, Inc. (ISRG) dominates the robotic-assisted surgery market with its da Vinci systems, driven by a "razor-and-blades" business model generating significant recurring revenue from consumables and services. The company exhibits strong financial health with high margins and capital allocation through share repurchases, making it attractive for growth-oriented North American investors seeking defensive qualities in healthcare innovation. Despite competitive pressures and regulatory risks, Intuitive Surgical's continuous technological advancements and international expansion provide substantial growth potential.
Dental Floss Market Is Going to Boom | 3M, Dr Wild & Co. AG, Sunstar Suisse SA, The humble Co.
The dental floss market is projected to grow from USD 727.6 million in 2026 to USD 978.9 million by 2033, exhibiting a CAGR of 6%. This growth is driven by innovation, increased investment, and changing regional dynamics, requiring strategic insights for decision-makers. The report offers detailed analysis including market segmentation, financial breakdowns of major players, and regional coverage to help stakeholders capitalize on market opportunities.
Nanobiotix Reports First Positive Phase 2 Data for NBTXR3 in Inoperable Stage 3 Lung Cancer
Nanobiotix (NBTX) announced positive initial Phase 2 data for its nanoradioenhancer NBTXR3 (JNJ-1900) in inoperable Stage 3 non-small cell lung cancer, presented by Johnson & Johnson. The trial demonstrated an acceptable safety profile with no serious adverse events and a promising 71.4% objective response rate. These results support Nanobiotix's strategy to position NBTXR3 as a scalable radioenhancer and strengthen its partnership with Johnson & Johnson.
Does J&J-Backed MRT-2359 Prostate Cancer Trial Change The Bull Case For Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics recently announced a Q4 2025 net loss and a supply agreement with Johnson & Johnson for a Phase 2 trial of MRT-2359 in metastatic castration-resistant prostate cancer. This collaboration, coupled with early positive data, validates Monte Rosa's molecular glue degrader platform. While the J&J deal and data strengthen MRT-2359 as a key catalyst, they don't fundamentally alter the risk profile related to clinical execution, trial outcomes, and funding needs for the loss-making company.
Global Knee Surgical Impactor Market to Reach USD 1,685.9 Million by 2036, Led by USA, China & India | Stryker, Zimmer Biomet, Johnson & Johnson Drive Precision Innovation
The global knee surgical impactor market is projected to grow to USD 1,685.9 million by 2036, exhibiting a 10.0% CAGR, driven by an aging population, rising osteoarthritis cases, and the need for precision in Total Knee Arthroplasty (TKA). The market, currently valued at USD 650.0 million in 2026, is seeing strong demand for advanced pneumatic and electro-pneumatic systems to ensure consistent implant alignment and reduce surgeon fatigue. The USA, China, and India are leading this growth, with companies like Stryker, Zimmer Biomet, and Johnson & Johnson spearheading innovation.
Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow
The Non-Muscle Invasive Bladder Cancer (NMIBC) market is projected to grow by $1 billion, reaching $4.82 billion by 2030, led by companies like Johnson & Johnson, Janssen Research & Development, and Merck & Co. This growth is primarily fueled by early diagnosis, increased use of transurethral resection, immunotherapy, chemotherapy, and advancements in personalized medicine. North America currently leads the market, with Asia-Pacific anticipated to show the fastest growth in the coming decade.
Nanobiotix Presents First Data From Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 In Stage 3 Inoperable Lung Cancer
Nanobiotix has announced preliminary data from the CONVERGE Phase 2 clinical trial for JNJ-1900 (NBTXR3) in stage 3 inoperable non-small cell lung cancer, presented at the 2026 European Lung Cancer Conference. The trial showed an acceptable safety profile with promising initial efficacy, including an objective response rate of 71.4% and a disease control rate of 100% in a subset of patients. JNJ-1900, a Nanoradioenhancer, is being developed under a collaboration with Johnson & Johnson and has previously received FDA Fast Track designation for head and neck squamous cell cancers.
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
NANOBIOTIX announced the presentation of initial data from the CONVERGE study, a randomized Phase 2 clinical trial assessing JNJ-1900 (NBTXR3) for Stage 3 inoperable non-small cell lung cancer. The study, sponsored by Johnson & Johnson, showed an acceptable safety profile and promising early efficacy responses, with an objective response rate of 71.4% and a disease control rate of 100% in initial patients after chemoradiotherapy. JNJ-1900 (NBTXR3) is a novel nanoradioenhancer designed to enhance tumor cell death when activated by radiotherapy, potentially triggering an immune response, and is being developed through a collaboration with Johnson & Johnson and The University of Texas MD Anderson Cancer Center.
With 20-plus years in drug development, Raj Pruthi joins PreveCeutical
PreveCeutical Medical Inc. (OTCQB: PRVCF) has appointed Dr. Raj S. Pruthi to its Board of Directors. Dr. Pruthi brings over 20 years of experience in academic medicine, global pharmaceutical leadership, and biotechnology innovation, with a focus on clinical development, regulatory strategy, and capital markets. He is expected to contribute significantly to the company's clinical development strategy, including its Sol-gel program, Nature Identical™ peptide platform, and therapies for pain management and Parkinson's disease.
NANOBIOTIX Announces Presentation of First Data from a
NANOBIOTIX announced the presentation of initial data from the CONVERGE study, a Johnson & Johnson-sponsored Phase 2 trial evaluating JNJ-1900 (NBTXR3) in patients with stage 3 inoperable non-small cell lung cancer. The data, presented at the 2026 European Lung Cancer Conference, showed an acceptable safety profile and promising initial efficacy responses with an overall response rate of 71.4% and a disease control rate of 100%. JNJ-1900 (NBTXR3) is a novel nanoradioenhancer designed to induce tumor cell death when activated by radiotherapy.
Kenvue Stock: Consumer Health Leader's Business Model, Competitive Position, and Investor Outlook IS
Kenvue Inc., spun off from Johnson & Johnson, is a consumer health giant known for brands like Tylenol and Neutrogena. The company operates through Self Care, Skin Health and Beauty, and Essential Health segments, maintaining a strong position in North American markets with its iconic brands and resilient business model. This article explores Kenvue's competitive advantages, sector drivers, and investor outlook, highlighting its potential for stable growth and dividend appeal for North American portfolios.
Bausch + Lomb Corp Stock: Eye Health Leader with Strong Product Portfolio and Growth Potential for Investors
Bausch + Lomb Corp (ISIN: CA07174N1090) is a major player in the vision care industry, offering a wide range of products including contact lenses, surgical equipment, and pharmaceuticals. The company leverages its long heritage, global distribution, and continuous innovation in lens technology and drug delivery to maintain a competitive edge. With an aging global population and rising demand for eye health solutions, Bausch + Lomb presents a defensive healthcare investment opportunity with growth potential for North American investors, despite risks related to supply chain, currency fluctuations, and regulatory hurdles.
Does J&J-Backed MRT-2359 Prostate Cancer Trial Change The Bull Case For Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics recently announced a fourth-quarter 2025 net loss but entered a significant supply agreement with Johnson & Johnson for its molecular glue degrader MRT-2359. This collaboration for a Phase 2 prostate cancer trial, alongside positive early data, validates Monte Rosa's platform and MRT-2359 as a key near-term catalyst. However, despite this external validation, the core investment risks related to clinical execution, trial outcomes, and funding needs for the loss-making company remain central to its investment narrative.
FDA Approves Johnson & Johnson Psoriasis Drug ICOTYDE
The FDA has approved Johnson & Johnson's oral drug ICOTYDE (icotrokinra) for treating moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older. The approval is based on Phase 3 clinical trials showing significant skin clearance and a favorable safety profile. ICOTYDE, a once-daily interleukin-23 receptor antagonist, offers a new systemic treatment option for millions affected by psoriasis.
AbbVie, Inc. Trade Ideas — BSESOF:4AB
This article compiles several trade ideas and analyses for AbbVie Inc. (ABBV) from different traders on TradingView. The analyses cover technical indicators, potential entry and exit points, support and resistance levels, and the company's fundamental position including its acquisition of Cerevel Therapeutics. Various traders offer bullish and bearish outlooks, suggesting different strategies for short-term and medium-term investments, with some noting the stock is nearing a critical juncture for either a breakout or a further decline.
Is Effexor’s First-in-Class GAD Approval in Japan Altering The Investment Case For Viatris (VTRS)?
Viatris Inc. recently secured approval in Japan for Effexor SR capsules as the first treatment for generalized anxiety disorder (GAD), expanding its market beyond depression. This move aligns with Viatris's strategy to pivot towards higher-value, innovative medicines from commoditized generics, reinforcing its investment narrative for gradually improving earnings. While promising, this approval alone doesn't shift the immediate focus on cost savings and managing margin pressures in its core generics business.
Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus
Eli Lilly's stock closed at $878.24 after the company announced a significant $2.75 billion licensing and research deal with Insilico Medicine. This comes as Lilly aims to diversify beyond its weight-loss drugs, with new trial data showing positive results for its psoriatic arthritis treatment combination and its eczema drug. The company continues to navigate competition and analyst adjustments to sales estimates for the obesity-drug sector.
Johnson & Johnson MedTech shares findings for Impella CP in left ventricle support
Johnson & Johnson MedTech's Abiomed unit presented new clinical findings for its Impella CP system at ACC 2026. The study focused on left ventricle support and whether pre-percutaneous coronary intervention (PCI) treatment reduces heart muscle damage. While overall findings were neutral, the research opens doors for future studies combining Impella with pharmacological therapies to optimize mechanical and pharmaceutical loading conditions.
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement
Monte Rosa Therapeutics (GLUE) is under scrutiny after a trial supply agreement with Johnson & Johnson for its MRT-2359 drug. While its price-to-sales ratio suggests overvaluation compared to its estimated fair value, a Discounted Cash Flow model indicates the stock is undervalued. This creates mixed signals for investors, highlighting the need to review underlying data and potential risks and rewards.
AbbVie Dermatology Data Highlights Immunology Depth And Emerging Skin Disease Opportunities
AbbVie is presenting new clinical research at the 2026 American Academy of Dermatology Annual Meeting, showcasing data from its dermatology portfolio with a focus on immune-mediated skin diseases like vitiligo and alopecia areata. This highlights AbbVie's strategy to extend its immunology expertise into focused dermatology markets, providing investors with insight into its R&D depth and potential for label expansions. While the company faces risks such as high debt and reliance on a few key drugs, successful clinical and commercial execution in dermatology could support its forecasted earnings growth.
Intuitive Surgical, Inc. stock: Leader in robotic-assisted surgery with strong analyst support and growth potential for North American investors
Intuitive Surgical, Inc. dominates the robotic surgery market with its da Vinci systems, exhibiting strong growth potential through its recurring revenue model from instruments and services. Analysts maintain a positive outlook with a "moderate buy" rating, citing expanding procedure volumes and the company's entrenched market position. Investors should monitor procedure trends, utilization rates, and the rollout of new systems while being aware of potential risks such as reimbursement changes and competition.
A Look At Bristol Myers Squibb (BMY) Valuation As Growth Portfolio Outperforms Recent GAAP Loss
Bristol-Myers Squibb (BMY) shows resilience despite recent share price fluctuations, with an intrinsic value estimate suggesting a 51% discount. The company's growth portfolio revenues increased by 17% to $22.6 billion in Full-Year 2024, although it reported a GAAP loss per share of $(4.41). Analysts estimate a fair value of $65 per share, indicating a potential undervaluation for the stock.
Amazon.com, Inc. Trade Ideas — BSESOF:AMZ
This article compiles several trade ideas and analyses for Amazon (AMZN) stock from various contributors on TradingView. It covers both bullish and bearish perspectives, utilizing technical indicators like MACD, RSI, and GEX to suggest potential price movements, support/resistance levels, and options strategies. Additionally, some analyses delve into Amazon's fundamental strengths, such as AWS growth, AI investments, and diverse company holdings, while also discussing broader market concepts like derivatives in emerging markets and commodity supercycles.
Pfizer Oncology Wins Raise Questions On Valuation Gap And Future Revenues
Pfizer recently announced positive Phase 2 results for atirmociclib in metastatic breast cancer and favorable Phase 3 data for TALZENNA in prostate cancer, highlighting progress in its oncology pipeline. These developments add new potential treatment areas and could significantly impact Pfizer's risk profile and revenue sources beyond its well-known vaccine and antiviral treatments. While Pfizer trades about 5% below analyst targets, Simply Wall St values shares 56.2% below fair value, emphasizing a substantial valuation gap.
JPMorgan Equity Premium Income ETF Sees Inflows Amid Decline
The JPMorgan Equity Premium Income ETF (JEPI) experienced a 1.82% decline in the past week but still saw a 5-day net inflow of $280.93 million. This inflow is attributed to market sentiment surrounding its major holdings, such as EOG Resources Inc., Johnson & Johnson, and Ross Stores, despite some mixed analyst outlooks and insider selling.
U.S. Hyaluronic Acid Based Dermal Fillers Market Size [2030]
The U.S. hyaluronic acid based dermal fillers market, valued at USD 1.53 billion in 2022, is projected to grow at a CAGR of 8.2% during the forecast period due to increasing awareness of cosmetic procedures and growing per capita income. Key factors driving market growth include the rising demand for minimally invasive cosmetic procedures among young people and the aging population, coupled with continuous product innovation and FDA approvals. However, the market faces restraints from the availability of alternative dermal fillers and concerns about temporary results or side effects.
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Protagonist Therapeutics, Inc. announced the presentation of one-year Phase 3 data for ICOTYDE (icotrokinra) at the 2026 American Academy of Dermatology Annual Meeting. The data reinforces ICOTYDE's potential as a differentiated oral therapy for moderate-to-severe plaque psoriasis, demonstrating lasting skin clearance and a favorable safety profile as a once-daily pill. This oral peptide specifically blocks the IL-23 receptor and is being developed and commercialized in collaboration with Johnson & Johnson.
ALLE (Allegion) Gross Property, Plant and Equipment : $1,130 Mil (As of Dec. 2025)
Allegion PLC (ALLE) reported its Gross Property, Plant and Equipment reached $1,130 million as of December 2025. GuruFocus rates ALLE with a GF Score of 98/100 and considers it Fairly Valued at $148.52, with the current stock price being $144.50. The article explains what Gross Property, Plant and Equipment signifies, its historical trend for Allegion, and provides a comparative analysis within the Business Services industry.
Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells $2,581,503.60 in Stock
Protagonist Therapeutics' CFO, Asif Ali, sold 24,765 shares of PTGX stock worth $2.58 million on March 26th, reducing his stake by nearly 29%. This follows earlier sales in January totaling approximately $4.55 million, indicating significant insider selling. Despite the insider sales and missed quarterly earnings expectations, analysts maintain a "Moderate Buy" consensus with an average target price of $107.31.
